2:15
Ben Jones on the Impact of Sequestration on Reimbursement
Ben Jones, Senior Director of Government Relations & Public Policy at McKesson Specialty H...
published: 05 Aug 2013
1:43
Dr. Schneiderman on Cancer Drugs and Futility Policies
Lawrence J. Dr. Schneiderman on Cancer Drugs and Futility Policies, MD, professor emeritu...
published: 18 Mar 2014
1:33
Dr. Vincent Miller Describes FoundationOne
Vincent Miller, MD, Chief Medical Officer, Foundation Medicine, describes the FoundationOn...
published: 18 Feb 2014
1:39
Dr. Howard L. Kaufman on the Implications of the Immunoscore
Howard L. Kaufman, MD, Rush University Medical Center, discusses the implications of the I...
published: 16 Jul 2013
1:12
Dr. Hudis Discusses Obesity as a Modifiable Risk Factor for Cancer
Clifford A. Hudis, MD, ASCO President-Elect and chief of the Breast Cancer Medicine Servic...
published: 06 Aug 2013
1:07
Dr. Partridge on the Adult Survivorship Program at Dana-Farber Cancer Institute
Ann H. Partridge, MD, MPH, from the Dana-Farber Cancer Institute, gives an overview of the...
published: 28 Jun 2013
author: OncLiveTV
1:18
Dr. Donato Discusses the National Marrow Donor Program
Michele L. Donato, MD, medical director, Blood and Marrow Collection Facility, John Theure...
published: 08 May 2014
0:45
Dr. Gogineni Comments on Oncology Drug Shortages
Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of...
published: 11 Jul 2013
author: OncLiveTV
0:56
Dr. Van Tine Discusses Identifying Biomarkers in Sarcomas
Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine ...
published: 12 Aug 2013
author: OncLiveTV
1:13
Dr. Bradley on the Agonist OX40 for the Treatment of Cancer
Edward Bradley, MD, Senior Vice President, Head, Innovative Medicines unit (iMED), MedImmu...
published: 28 Aug 2013
1:16
Dr. Brahmer on Distinguishing Between Immunotherapy Response and Cancer Growth
Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comp...
published: 30 Oct 2013
2:01
Dr. Estey Discusses the FDA Approval Process
Elihu H. Estey, MD, professor of medicine, University of Washington School of Medicine, Fr...
published: 18 Dec 2013
1:40
Dr. Adjei on Adverse Events From MEK Inhibitors
Alex A. Adjei, MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia ...
published: 11 Sep 2013
1:08
Dr. Rapoport Discusses Hyponatremia in Patients With Cancer
Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Lang...
published: 22 Nov 2013
Youtube results:
1:46
Dr. Goy Comments on Recent Developments in the Field of Immunology
Andre Goy, MD, Chairman and Director and Chief of Lymphoma at John Theurer Cancer Center, ...
published: 14 Aug 2013
author: OncLiveTV
1:30
Dr. Brahmer Discusses the Management of Adverse Events From Immunotherapy
Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comp...
published: 26 Sep 2013
1:20
Dr. Hudis on the Optimism Surrounding Immunotherapy
Clifford A. Hudis, MD, ASCO President, Chief, Breast Cancer Medicine Service, Attending Ph...
published: 26 Sep 2013
1:09
Dr. Carvajal on the Investigation of Selumetinib for Uveal Melanoma
Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discu...
published: 25 Jul 2013
author: OncLiveTV
×







×